CAR T-Cells for CNS Lymphoma: Driving into New Terrain?

Exome sequencing identifies SLIT2 variants in primary CNS lymphoma

(2021) Leon D. Kaulen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report

(2021) Kai Rejeski et al.   BMC INFECTIOUS DISEASES

Therapeutic Delivery to Central Nervous System

(2021) Katherine E. Kunigelis et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

CAR T cells and checkpoint inhibition for the treatment of glioblastoma

(2020) Steven H. Shen et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Management and outcome of primary CNS lymphoma in the modern era

(2020) Caroline Houillier et al.   NEUROLOGY

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas

(2020) Katrin Aslan et al.   Nature Communications

Primary dural lymphomas: Clinical presentation, management, and outcome

(2020) Philipp Karschnia et al.   CANCER

In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy

(2020) Lukas Marcelis et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

(2020) Nirali N. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Human chimeric antigen receptor macrophages for cancer immunotherapy

(2020) Michael Klichinsky et al.   NATURE BIOTECHNOLOGY

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL

(2020) Felix Korell et al.   Cells

Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy

(2020) Sheng-I Hu et al.   Annals of Translational Medicine

Autoimmune disease-related primary CNS lymphoma: systematic review and meta-analysis

(2020) Leon D. Kaulen et al.   JOURNAL OF NEURO-ONCOLOGY

Direct convective delivery of adeno-associated virus gene therapy for treatment of neurological disorders

(2020) Russell R. Lonser et al.   JOURNAL OF NEUROSURGERY

CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain

(2020) Tongjuan Li et al.   Frontiers in Oncology

DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality

(2020) Kitsada Wudhikarn et al.   Blood Advances

Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma

(2020) Paolo Strati et al.   Blood Advances

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

(2020) Tania Jain et al.   Blood Advances

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies

(2020) Kevin R. Parker et al.   CELL

The cerebroventricular environment modifies CAR T cells for potent activity against both central nervous system and systemic lymphoma

(2020) Xiuli Wang et al.   Cancer Immunology Research

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy

(2020) Zhen Zhang et al.   Journal for ImmunoTherapy of Cancer

Cytokine Storm

(2020) David C. Fajgenbaum et al.   NEW ENGLAND JOURNAL OF MEDICINE

Next-generation cell therapies: the emerging role of CAR-NK cells

(2020) Rafet Basar et al.   Blood Advances

Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy

(2020) Khushali S. Jhaveri et al.   Blood Advances

Pharmacologic management of cognitive impairment induced by cancer therapy

(2019) Philipp Karschnia et al.   LANCET ONCOLOGY

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma

(2019) Stephanie L. Goff et al.   JOURNAL OF IMMUNOTHERAPY

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells

(2019) Philipp Karschnia et al.   BLOOD

Tisagenlecleucel CAR-T Cell Therapy in Secondary CNS Lymphoma

(2019) Matthew J. Frigault et al.   BLOOD

Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma

(2019) Leon D. Kaulen et al.   JOURNAL OF NEURO-ONCOLOGY

CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy

(2019) Joshua A. Hill et al.   BLOOD REVIEWS

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy

(2019) Julia Ruark et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma

(2019) Tanya Siddiqi et al.   BLOOD

Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice

(2019) Matthias Mulazzani et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

(2019) Michael C. Burger et al.   Frontiers in Immunology

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

(2019) Sanfang Tu et al.   Frontiers in Oncology

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

(2018) Tarec Christoffer El-Galaly et al.   EUROPEAN JOURNAL OF CANCER

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

(2018) Margherita Norelli et al.   NATURE MEDICINE

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

(2018) Bianca D. Santomasso et al.   Cancer Discovery

Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors

(2018) Vincent Yi Sheng Oei et al.   Cancer Immunology Research

Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system

(2018) Soo Jeong Nam et al.   OncoImmunology

Targeting Macrophages in Cancer: From Bench to Bedside

(2018) Ashleigh R. Poh et al.   Frontiers in Oncology

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015

(2018) Quinn T Ostrom et al.   NEURO-ONCOLOGY

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

(2018) Rosalie M. Sterner et al.   BLOOD

Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report

(2018) Xia Xiao et al.   CLINICAL CANCER RESEARCH

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group

(2017) B Kasenda et al.   LEUKEMIA

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

(2017) Andras Heczey et al.   MOLECULAR THERAPY

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma

(2017) Jeremy S. Abramson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas

(2017) D Yan et al.   ONCOGENE

Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma

(2017) Khun Visith Keu et al.   Science Translational Medicine

The role of autologous stem cell transplantation in primary central nervous system lymphoma

(2016) A. J. M. Ferreri et al.   BLOOD

PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR

(2016) Elise A. Chong et al.   BLOOD

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

The role of microglia and macrophages in glioma maintenance and progression

(2016) Dolores Hambardzumyan et al.   NATURE NEUROSCIENCE

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial

(2016) Gerald Illerhaus et al.   Lancet Haematology

TRUCKs: the fourth generation of CARs

(2015) Markus Chmielewski et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines

(2014) Peter J. Murray et al.   IMMUNITY

CNS Lymphoma

(2014) Caterina Giannini et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice

(2013) Martina Deckert et al.   ACTA NEUROPATHOLOGICA

How I treat CNS lymphomas

(2013) J. L. Rubenstein et al.   BLOOD

EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

(2013) J. H. Sampson et al.   CLINICAL CANCER RESEARCH

Diagnosis and treatment of primary CNS lymphoma

(2013) Agnieszka Korfel et al.   Nature Reviews Neurology

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

(2012) B. G. Till et al.   BLOOD

How I treat primary CNS lymphoma

(2011) A. J. M. Ferreri   BLOOD

IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression

(2011) M. Chmielewski et al.   CANCER RESEARCH

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

(2009) H. Xin et al.   CANCER RESEARCH

Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication

(2009) Xiao-Song Zhong et al.   MOLECULAR THERAPY